Citadel Advisors’s Briacell Therapeutics BCTX Stock Holding History

Citadel Advisors’s Portfolio BCTX Stock Details BCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-39	Closed	-$3.28K	–	14468
2024 Q4	$3.28K	Buy	+39	New	+$4.67K	﹤0.01%	14005
2024 Q3	–	Sell	-39	Closed	-$6.61K	–	14247
2024 Q2	$6.61K	Buy	39 +3	+8%	+$849	﹤0.01%	13318
2024 Q1	$15.4K	Buy	36 +29	+414%	+$16K	﹤0.01%	13186
2023 Q4	$6.43K	Buy	+7	New	+$5.02K	﹤0.01%	13351
2022 Q2	–	Sell	-379	Closed	-$577K	–	12873
2022 Q1	$577K	Sell	379 -2,066	-84%	-$2.44M	﹤0.01%	9051
2021 Q4	$3.04M	Buy	+2,445	New	+$3.2M	﹤0.01%	5313

Other funds holding BCTX

FHA

Flagship Harbor Advisors Boston, Massachusetts $2.61B AUM 23.21% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Allworth Financial Folsom, California $24.7B AUM 15.55% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

SSA

SSA Swiss Advisors Zurich $216M AUM 17.86% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Citadel Advisors's BCTX Position: Q4 2025 in Review

Citadel Advisors sold out of Briacell Therapeutics (BCTX) in Q4 2025, closing a stake of 11,055 shares — an estimated $122K sold.

Citadel Advisors first reported a position in BCTX in Q2 2023 and held it in 5 quarters. The position peaked at $409K in Q2 2023. 13 funds tracked by Wall St. Rank hold BCTX as of Q4 2025.

Citadel Advisors reported no remaining Briacell Therapeutics position as of Q4 2025 after selling out during the quarter.
Citadel Advisors sold 11,055 Briacell Therapeutics shares in Q4 2025, an estimated $122K.
Citadel Advisors first reported a position in Briacell Therapeutics in Q2 2023 and held it in 5 quarters.
Citadel Advisors's Briacell Therapeutics position peaked at $409K in Q2 2023.
13 funds tracked by Wall St. Rank held Briacell Therapeutics as of Q4 2025.

Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.